Skip to content
DataLookout
Menu

NCT07534397

Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

StatusEnrolling by Invitation
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial status changed: Recruiting → Enrolling by Invitation
    • Site details revised
  2. Notable Recruitment opened Show 5 more changesShow less
    • Eligibility criteria expanded, about 37 words
    • Start date changed from estimate of Aug 1, 2026 to Sep 15, 2026
    • Secondary endpoints: details revised at 16 of 16 entries
    • Study description expanded, about 6 words
    • Site details revised
  3. Notable Eligibility criteria expanded, about 22 words
    • Collaborators expanded, about 6 words
    v4
  4. Notable Start date: May 1, 2026 to Aug 1, 2026v3
  5. Notable Primary endpoint(s) modified
    • Secondary endpoints revised (16)
    • Study description expanded, about 1 word
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency
Timeframe: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency
Timeframe: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on Phonemic Fluency
Timeframe: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Phonemic Fluency
Timeframe: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment

Secondary (16)

Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during overt reading
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during overt reading
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during self-generated speech
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during self-generated speech
Treatment group differences in change from Baseline to 1-week Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score.
Show 11 moreShow less
Treatment group differences in change from Baseline to 2-month Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score.
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during overt reading
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during overt reading
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during self-generated speech
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during self-generated speech
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during overt reading
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during overt reading
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during self-generated speech
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during self-generated speech
Treatment group differences in change from Baseline to 1-week Post-treatment on Freezing of Gate during the timed up and go task
Treatment group differences in change from Baseline to 2-month Post-treatment on Freezing of Gate during the timed up and go task

Arms and interventions

Transcranial direct current stimulationExperimental

Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds. Other Names: tDCS 1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10

Sham transcranial direct current stimulationSham comparator

Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.

Devices: transcranial direct current stimulation, Sham transcranial direct current stimulation

Sites

1 site in 1 country

  • Callier Clinical Center, The University of Texas at DallasRichardson, Texas, United States